MELBOURNE, Fla., Oct. 22, 2018 /PRNewswire-PRWeb/ -- Erchonia, the leading low-level laser technology manufacturer in
Board-certified dermatologist, Dr. Glynis R. Ablon, MD, discusses and demonstrates the Lunula Laser's unique capacity to zap away toe nail fungus. While other treatment options provide unsuccessful, painful or harmful results in comparison to the FDA Market Cleared Lunula Laser. Toe nail fungus is not only a U.S. problem, but a world-wide problem. It is estimated that 10% of the world is plagued by this condition.
In contrast to high-power, high-heat lasers which have been used to treat toe nail fungus, the new Lunula Laser produces a low-level or cold output that is non-thermal with no effect on the body's tissue or nail bed. Instead, the non-invasive Lunula Laser offers impressive clinical response stemming from its two therapeutic wavelengths: 405 nm (violet) and 635 nm (red). Each wavelength performs a very specific function to provide a comprehensive solution for toe nail fungus.
"We were so pleased with the patient's results and think "The Doctors" segment is the perfect way to introduce the Lunula Laser to a national audience," says Charlie Shanks, VP of Erchonia Corporation. "We know our Lunula Laser can help so many people achieve healthy, clear nail growth without experiencing any harmful side-effects."
About Erchonia A small family company is changing the world with the most advanced non-invasive lasers on the market. Erchonia went from starting in a small garage in 1996 to selling their products in over 50 different countries around the world in 2018. Erchonia has been passionate about researching and developing low level lasers since the beginning with over (14) FDA clearances for treating chronic pain and promoting fat loss. As this family has grown so has the world of non-invasive drug-free healthcare solutions.
Subscribe to our Free Newsletters!